Lilly Right-Sizes Sales Force As It Pushes Its Pipeline Forward
This article was originally published in The Pink Sheet Daily
The pharma is cutting costs as it continues to reel from revenues lost to generic competition. Meanwhile, it moves its late-stage pipeline forward in hopes of filling the gaps.
You may also be interested in...
Novartis posted solid growth of 9% in Q1 in emerging markets, with China sales up 21%; Lilly reports strong sales in China lifted revenues by 11%.
J&J is the first pharma company to bring an SGLT2 inhibitor to market, but its window of exclusivity in that class may be narrow, given that FDA is slated to assess two other SGLT2s later this year.
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.